MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 20, 2005; DOI: 10.1124/mol.105.012278


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.012278v1
68/3/855    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J.
Right arrow Articles by Zhang, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J.
Right arrow Articles by Zhang, S.


Received for publication February 25, 2005.
Revised June 16, 2005.
Accepted for publication June 20, 2005.

Intracellular K+ is required for the inactivation-induced high affinity binding of cisapride to HERG channels

Jijin Lin 1, Jun Guo 1, Hongying Gang 1, Peter Wojciechowski 1, Jeffrey T Wigle 1, Shetuan Zhang 1*

1 University of Manitoba

* Address correspondence to: E-mail: szhang{at}sbrc.ca

Abstract

Many commonly used medications can cause long QT syndrome and thus increase the risk of life-threatening arrhythmias. High-affinity HERG (the Human Ether-a-go-go-Related Gene) potassium channel blockade by structurally diverse compounds is almost exclusively responsible for this side effect. Understanding drug-HERG channel interactions is an important step in avoiding drug-induced long QT syndromes. Previous studies have found that disrupting HERG inactivation reduces the degree of drug block and suggested that the inactivated state is the preferential state for drug binding to HERG channels. However, recent studies have also shown that inactivation does not dictate drug sensitivity of HERG channels. In the present study we have examined the effect of inactivation gating on cisapride block of HERG. Modulation of HERG inactivation was achieved by either changing extracellular K+ or Cs+ concentration or by mutations of the channel. We found that while inactivation facilitated cisapride block of the HERG K+ current, inactivation was not coupled with cisapride block of HERG when the Cs+ current was recorded. Furthermore, cisapride block of the HERG K+ current was not linked with inactivation in the mutant HERG channels F656V and F656M. Our results suggest that inactivation, through affecting the positioning of F656, facilitates cisapride block of HERG channels.


Key words: Ion channel regulation, Potassium, Structure-activity relationships and modeling, Mutagenesis/Chimeric approaches, Structure/function/mechanism


This article has been cited by other articles:


Home page
JGPHome page
H. Gang and S. Zhang
Na+ Permeation and Block of hERG Potassium Channels
J. Gen. Physiol., June 26, 2006; 128(1): 55 - 71.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Guo, H. Gang, and S. Zhang
Molecular Determinants of Cocaine Block of Human Ether-a-go-go-Related Gene Potassium Channels
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 865 - 874.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Zhang
Isolation and characterization of IKr in cardiac myocytes by Cs+ permeation
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1038 - H1049.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S.-B. Yang, F. Major, L. F. Tietze, and M. Rupnik
Block of Delayed-Rectifier Potassium Channels by Reduced Haloperidol and Related Compounds in Mouse Cortical Neurons
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 352 - 362.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics